We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Joseph Aloi

Joseph A. Aloi MD

Professor of Internal Medicine and Chief, Section on Endocrinology and Metabolism, Wake Forest School of Medicine, Winston-Salem, North Carolina

Dr. Joseph Aloi's early career centered on neuroendocrine responses to pharmacologic challenges in a variety of affective disorders while working as a chemist at the National Institutes of Health. The time spent in the development of trial strategy, conduct of the trial, with subsequent analysis of the data allowed him to develop an expertise in multiple phases of clinical investigation. During his training as a physician at the University of Virginia, Dr. Aloi migrated into the area of reproductive neuro-endocrinology, bridging investigations ranging from rodent models to clinical trial work in women with polycystic ovary syndrome and neuroendocrine function in the geriatric population. He advanced his clinical practice upon becoming a faculty member at the University of Virginia and pursued clinical trials with cardiovascular endpoints for persons with type 2 diabetes – being an investigator in the ADOPT, EXAMINE and EMPA-reg trials. Dr. Aloi transitioned to detection and prevention of type 2 diabetes as Section Chief of Endocrine at the Eastern Virginia Medical School, as experience in these trials convinced him that to impact the growth trajectory of diabetes, it is necessary to prevent diabetes through early detection and lifestyle/pharmacologic intervention. To conduct these efforts efficiently and on a large scale, integrating the clinical assessment with technology, is his current and most important focus as Division of Endocrinology Chief at Wake Forest School of Medicine and current Chair of the American Diabetes Technology Interest Group.

 

Disclosures

Dr. Aloi has served as an advisor to Medtronic Diabetes and received research funding from Medtronic Diabetes and Abbott Diabetes.